Valo Health Appoints Chris Anagnostopoulos, PhD, as Chief Causal AI Officer

Data science leader to advance Valo’s leading human causal biology platform for drug discovery

LEXINGTON, Mass.--(BUSINESS WIRE)--Valo Health, Inc. (“Valo”), a pioneer in the use of human data and AI to accelerate drug discovery and development, today announced the appointment of Chris Anagnostopoulos, PhD, C.Stat, to the newly created position of Chief Causal AI Officer. In this role, Dr. Anagnostopoulos will lead the advancement of Valo’s human causal biology platform, translating large-scale, real‑world human data into causal insights that inform drug discovery.

Valo aims to improve clinical success rates by refining how diseases are classified, uncovering causal drivers earlier in drug discovery, and developing novel therapeutics for specific patient groups. The company has unique access to longitudinal real-world data from more than 20 million patients, including records spanning 20–30 years and linked genomic information. Valo uses AI/ML to identify patient subtypes in this real-world data, and advanced causal inference techniques to infer the causal drivers of disease, and how to intervene. These human-validated causal insights then feed directly into Valo’s predictive chemistry platform, enabling the rapid development of novel therapeutics grounded in human biology and designed for clinical success.

“The creation of this position and strategic appointment underscore the importance we place on human causal evidence as the foundation of drug discovery, and the opportunity we see for causal AI/ML tools to help solve the translational gap,” said Brian Alexander, MD, MPH, CEO of Valo Health. “Dr. Anagnostopoulos brings an exceptionally rare skill set at the intersection of AI, statistics, and human biology. His expertise will be instrumental as we continue scaling this capability, enabling a new era of drug discovery that is anchored in human causal biology.”

Dr. Anagnostopoulos is a seasoned AI and life sciences innovation leader with more than two decades of experience spanning academia, global consulting, technology startups, and leading biopharmaceutical companies. He joins Valo from QuantumBlack, AI by McKinsey, where he served as Tech Fellow Partner, Global Director of AI Innovation in Life Sciences, and co‑founder of McKinsey’s Scientific AI service line, driving the application of causal machine learning and advanced analytics across biopharma R&D. Previously, Dr. Anagnostopoulos held senior leadership roles at the technology unicorn Improbable and was also an Associate Professor at Imperial College London.

“Drug discovery is struggling with a widening clinical translation gap, which consistently drives low clinical trial success rates, despite a growing number of drug candidates,” said Dr. Anagnostopoulos. “Addressing this causal gap requires integrating human causal biology insights as early as possible in drug discovery. Valo’s platform represents a truly differentiated way to do this, extracting causal mechanisms of disease from deep human data. I’m thrilled to join this talented team and work together to fully leverage causal AI to advance human health.”

Dr. Anagnostopoulos was a Research Fellow in the prestigious Statistical Laboratory at Cambridge University, and holds a PhD in Statistics from Imperial College London, as well as two MSc degrees, one in Machine Learning from the University of Edinburgh, and one in Theoretical Computer Science from the University of Athens. He earned his undergraduate degree in Mathematics at Cambridge University. He is a Chartered Statistician (C.Stat) of the Royal Statistical Society and currently serves as an Honorary Associate Professor at Imperial College London.

About Valo Health:

Valo is redefining drug discovery and development through its AI-enabled human causal biology and closed loop chemistry platforms. Valo uses AI to understand disease causality, identify patient subtypes across heterogeneous diseases, and pinpoint novel drug targets. The Company validates targets using proprietary 3D engineered human tissue models that mimic mature human physiology and structure. The Company’s closed loop chemistry platform enables rapid development of potential molecules from trillions of starting points. Valo’s approach aims to identify more impactful drug targets and small molecule therapeutics, faster, and with greater precision than traditional R&D methods. The Company works with leading global pharmaceutical partners, including Novo Nordisk and Merck KGaA, Darmstadt, Germany, in addition to advancing its own pipeline. Valo was founded by Flagship Pioneering in 2019. Follow us on LinkedIn and X.

Media Contact:
Erin Smith
esmith@valohealth.com